News

Analysis of the American Rheumatology Network-Trio Health (ARN-Trio) registry finds a surge in new prescriptions for Merck’s Renflexis infliximab biosimilar. The ARN-Trio registry is the first rheumatology registry to combine pharmacy dispensing data with electronic medical records (EMR) to provide unparalleled real-world insights. ARN-Trio is the largest registry of biosimilar use in community rheumatology practice, […]

Analysis of the American Rheumatology Network-Trio Health (ARN-Trio) registry finds that AbbVie’s Rinvoq use is increasing rapidly as a proportion of JAK inhibitor use. Rheumatologists are asking, why is use of AbbVie’s Rinvoq increasing so rapidly? Given the higher cost of Rinvoq (annual net price $44,035) and similar safety and efficacy across the JAK inhibitor

American Rheumatology Network (ARN) and Trio Health (Trio) have launched the first rheumatology registry that combines pharmacy dispensing data with electronic medical records (EMR) to provide unparalleled real-world insights into patient experiences and outcomes. The new database includes over 75,000 patients within the ARN’s national network, serving as a comprehensive data solution that combines EMR,

The American Rheumatology Network (ARN) has been so successful with cost management, particularly via the use of biosimilars, that it believes its model is worthy of emulation, said Colin C. Edgerton, MD, executive chairman of ARN, who spoke on the subject recently in an Academy of Managed Care Pharmacy–sponsored webinar. “Certainly, rheumatologists are eager to

by Colin Edgerton We are seeing COVID-19 cases peak in many areas of the US, prompting thoughts about what comes next for rheumatology practices. Many community rheumatology practices have been hit hard by the crisis, and we hope that sharing “lessons learned” will inform practices on what steps to take now, and what to anticipate

As of 12:30pm ET on March 17, 2020 CMS has sent out an official notification stating that effective for services starting March 6, 2020 (retroactive), the limitations on where Medicare patients are eligible for telehealth services has been removed during the emergency. The waiver temporarily eliminates the requirement that the originating site must be a

Updated March 17, 2020 3:00pm American Rheumatology Network (ARN) members are concerned about safe access to care during the COVID-19 pandemic. The Centers for Disease Control and Prevention (CDC) has recommended use of telehealth, when clinically appropriate, to lessen the risk of disease transmission. CDC recommendations are fluid and rapidly changing, and rheumatologists and rheumatology

Originally published in The Rheumatologist The Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule final rule for 2020 includes a big win for rheumatologists—a 15% increase in reimbursement for evaluation and management (E/M) services. This decision represents an historic hike in payment for these codes and resulted from 10 years of advocacy work

Charleston, SC, Feb. 18, 2020 – American Rheumatology Network (ARN) announces their partnership with Framework Management Information, Inc. (Framework) to develop AXCESS1, a new prescription access hub. AXCESS1 seamlessly interfaces with healthcare practices, specialty pharmacies, and pharmaceutical manufacturers serving as a “one-stop shop” for information pertaining to prior authorization status, patient assistance programs, and medication

Originally published in Biosimilar Development In the first installment of this four-part series, the members of the Biosimilar Development Editorial Board and friends discussed how 2019 turned out for the biosimilar industry. But as we face 2020, several big questions remain from the past year and about what the future may (or may not) bring